Clinical Oncology
Volume 20, Issue 6 , Pages 463-469 , August 2008

Adjuvant Chemotherapy in Endometrial Carcinoma: Overview of Randomised Trials

  • T. Hogberg

      Affiliations

    • Corresponding Author InformationAuthor for correspondence: T. Hogberg, Department of Cancer Epidemiology, Tumor Registry, University Hospital, SE-22185, Lund, Sweden. Tel: +46 46 17 75 50.

Received 28 February 2008 ,Revised 18 March 2008 ,Accepted 1 April 2008.

References 

  1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin. 2005;55(2):74–108
  2. The National Board of Health and Welfare Centre for Epidemiology . Cancer incidence in Sweden 2006. Available from: http://www.socialstyrelsen.se/Statistik/statistik_amne/Cancer
  3. Creasman WT, Odicino F, Maisonneuve P, et al. Carcinoma of the corpus uteri. FIGO 6th annual report on the results of treatment in gynecological cancer. Int J Gynaecol Obstet. 2006;95(Suppl 1):S105–S143
  4. Humber CE, Tierney JF, Symonds RP, et al. Chemotherapy for advanced, recurrent or metastatic endometrial cancer: a systematic review of Cochrane collaboration. Ann Oncol. 2007;18(3):409–420
  5. Aapro MS, van Wijk FH, Bolis G, et al. Doxorubicin versus doxorubicin and cisplatin in endometrial carcinoma: definitive results of a randomised study (55872) by the EORTC Gynaecological Cancer Group. Ann Oncol. 2003;14(3):441–448
  6. Thigpen JT, Brady MF, Homesley HD, et al. Phase III trial of doxorubicin with or without cisplatin in advanced endometrial carcinoma: a Gynecologic Oncology Group study. J Clin Oncol. 2004;22(19):3902–3908
  7. Fleming GF, Brunetto VL, Cella D, et al. Phase III trial of doxorubicin plus cisplatin with or without paclitaxel plus filgrastim in advanced endometrial carcinoma: a Gynecologic Oncology Group study. J Clin Oncol. 2004;22(11):2159–2166
  8. Sorbe B, Andersson H, Boman K, Rosenberg P, Kalling M. Treatment of primary advanced and recurrent endometrial carcinoma with a combination of carboplatin and paclitaxel – long-term follow-up. Int J Gynecol Cancer, in press. doi:10.1111/j.1525-1438.2007.01094.x.
  9. National Cancer Institute . GOG-209. Available from: http://www.cancer.gov/search/ViewClinicalTrials.aspx?cdrid=305940&protocolsearchid=4206096&version=healthprofessional
  10. Randall ME, Filiaci VL, Muss H, et al. Randomized phase III trial of whole-abdominal irradiation versus doxorubicin and cisplatin chemotherapy in advanced endometrial carcinoma: a Gynecologic Oncology Group study. J Clin Oncol. 2006;24(1):36–44
  11. McMeekin DS, Filiaci VL, Thigpen JT, Gallion HH, Fleming GF, Rodgers WH. The relationship between histology and outcome in advanced and recurrent endometrial cancer patients participating in first-line chemotherapy trials: a Gynecologic Oncology Group study. Gynecol Oncol. 2007;106(1):16–22
  12. Morrow CP, Bundy BN, Homesley HD, et al. Doxorubicin as an adjuvant following surgery and radiation therapy in patients with high-risk endometrial carcinoma, stage I and occult stage II: a Gynecologic Oncology Group study. Gynecol Oncol. 1990;36(2):166–171
  13. Maggi R, Lissoni A, Spina F, et al. Adjuvant chemotherapy vs radiotherapy in high-risk endometrial carcinoma: results of a randomised trial. Br J Cancer. 2006;95(3):266–271
  14. Susumu N, Sagae S, Udagawa Y, et al. Randomized phase III trial of pelvic radiotherapy versus cisplatin-based combined chemotherapy in patients with intermediate- and high-risk endometrial cancer: a Japanese Gynecologic Oncology Group study. Gynecol Oncol. 2008;108:226–233
  15. Hogberg T, Rosenberg P, Kristensen G, et al. A randomized phase-III study on adjuvant treatment with radiation (RT)±chemotherapy (CT) in early stage high-risk endometrial cancer (NSGO-EC-9501/EORTC 55991). J Clin Oncol. 2007;25(18S):[abstract 5503]
  16. Greven K, Winter K, Underhill K, Fontenesci J, Burke T. Final analysis of RTOG 9708: adjuvant postoperative irradiation combined with cisplatin/paclitaxel chemotherapy following surgery for patients with high-risk endometrial cancer. Gynecol Oncol. 2006;103(1):155–159
  17. National Cancer Institute . PORTEC 3. Available from: http://www.cancer.gov/search/ViewClinicalTrials.aspx?cdrid=521447&protocolsearchid=4206096&version=healthprofessional
  18. Dell'Anna T, Buda A, Floriani I. Adjuvant chemotherapy for endometrial cancer. The Cochrane Library Available from: http://www.thecochranelibrary.com2008;
  19. Zee BC. Planned equivalence or noninferiority trials versus unplanned noninferiority claims: are they equal?. J Clin Oncol. 2006;24(7):1026–1028
  20. Orton J, Blake P. Adjuvant external beam radiotherapy (EBRT) in the treatment of endometrial cancer: results of the randomised MRC ASTEC and NCIC CTG EN.5 trial. J Clin Oncol. 2007;25(18S):[abstract 5504]
  21. Hogberg T, Glimelius B, Nygren P. A systematic overview of chemotherapy effects in ovarian cancer. Acta Oncol. 2001;40(2–3):340–360

PII: S0936-6555(08)00169-6

doi: 10.1016/j.clon.2008.04.001

Clinical Oncology
Volume 20, Issue 6 , Pages 463-469 , August 2008

Article Tools